JP2024507294A - 治療方法 - Google Patents

治療方法 Download PDF

Info

Publication number
JP2024507294A
JP2024507294A JP2023574302A JP2023574302A JP2024507294A JP 2024507294 A JP2024507294 A JP 2024507294A JP 2023574302 A JP2023574302 A JP 2023574302A JP 2023574302 A JP2023574302 A JP 2023574302A JP 2024507294 A JP2024507294 A JP 2024507294A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
subject
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507294A5 (https=
Inventor
エス カラー，バリー
マイケル ギブソン，シー
ホフ，アルナウト ウェー イェー ファント
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celecor Therapeutics Inc
Original Assignee
Celecor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celecor Therapeutics Inc filed Critical Celecor Therapeutics Inc
Publication of JP2024507294A publication Critical patent/JP2024507294A/ja
Publication of JP2024507294A5 publication Critical patent/JP2024507294A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023574302A 2021-02-17 2022-02-16 治療方法 Pending JP2024507294A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150301P 2021-02-17 2021-02-17
US63/150,301 2021-02-17
PCT/US2022/016571 WO2022177968A1 (en) 2021-02-17 2022-02-16 Therapeutic methods

Publications (2)

Publication Number Publication Date
JP2024507294A true JP2024507294A (ja) 2024-02-16
JP2024507294A5 JP2024507294A5 (https=) 2025-02-25

Family

ID=82931154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574302A Pending JP2024507294A (ja) 2021-02-17 2022-02-16 治療方法

Country Status (10)

Country Link
US (1) US20250268902A1 (https=)
EP (1) EP4294402A4 (https=)
JP (1) JP2024507294A (https=)
KR (1) KR20230157354A (https=)
CN (1) CN117098538A (https=)
AU (1) AU2022224562A1 (https=)
BR (1) BR112023016459A2 (https=)
CA (1) CA3211215A1 (https=)
MX (1) MX2023009620A (https=)
WO (1) WO2022177968A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019771A1 (en) * 2024-07-15 2026-01-22 Celecor Therapeutics, Inc. Zalunfiban for use in the treatment of thrombotic disorder in patients with renal impairment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2804610B1 (en) * 2012-01-16 2018-10-31 The Rockefeller University Organic compounds
US11684622B2 (en) * 2018-06-19 2023-06-27 Celecor Therapeutics, Inc. Deuterated RUC-4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. AM. HEART ASSOC., vol. 9, JPN6025052982, 2020, pages 016552, ISSN: 0005766081 *

Also Published As

Publication number Publication date
WO2022177968A1 (en) 2022-08-25
EP4294402A4 (en) 2025-01-15
MX2023009620A (es) 2023-11-01
WO2022177968A9 (en) 2022-10-20
EP4294402A1 (en) 2023-12-27
CA3211215A1 (en) 2022-08-25
CN117098538A (zh) 2023-11-21
BR112023016459A2 (pt) 2023-10-10
KR20230157354A (ko) 2023-11-16
AU2022224562A1 (en) 2023-08-31
WO2022177968A8 (en) 2022-11-17
US20250268902A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
Goto et al. Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice
JP2020535227A5 (https=)
JP7818412B2 (ja) デュラグルチドを使用する方法およびデュラグルチドを含有する組成物
McCrystal et al. Phase I study of the cytotoxic agent N-[2-(dimethylamino) ethyl] acridine-4-carboxamide
JP2025148495A (ja) Ｂ因子阻害剤の使用方法
US20220073888A1 (en) Combination treatment
IL268930B2 (en) Citrulline for the treatment of sickle cell crisis
JP2024507294A (ja) 治療方法
TW201125562A (en) Sustained release fampridine treatment in patients with multiple sclerosis
CA3074563A1 (en) Sublingual epinephrine tablets
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
Bracht et al. Cyclosporine A and control of vascular tone in the human forearm: influence of post-transplant hypertension
JP2024507294A5 (https=)
US11707439B2 (en) Parenteral treatments involving aminoadamantane derivatives
JPH06228007A (ja) トロンビンの直接的阻害剤を活性成分とする血栓溶解剤
ES2904256T3 (es) Métodos para tratar, reducir la incidencia de y/o prevenir eventos isquémicos
KR20220018959A (ko) 6,8-비스-벤질티오-옥타노산을 사용한 림프종 치료를 위한 치료 방법 및 조성물
TW200418468A (en) Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events
WO2025209479A1 (en) Methods of treatment of immune thrombocytopenia using sovleplenib
JP2024510926A (ja) バダデュスタットの薬物間相互作用の調節
WO2026019771A1 (en) Zalunfiban for use in the treatment of thrombotic disorder in patients with renal impairment
WO2025120013A1 (en) Compositions and methods for treating depression disorders
WO2024089196A1 (en) Recombinant apyrase protein for use in the treatment of an ischemic event at a dose of 40-240 mg
Aronson MG Franzosi and R. Latini
JP2024502821A5 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403